Denocabtagene Ciloleucel(Beijing Yongtai Ruike Biotechnology Company)

迪诺仑赛

Report date: 2025/06/12 20:00:09

Base Information

Drug NameDenocabtagene Ciloleucel(Beijing Yongtai Ruike Biotechnology Company)

Drug Alias NameDinorencelRC19D2CAR-T-19-D2RC19-D2CAR-T-19-DNR

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19Anti-TGF-βImmunologic cytotoxicity +[4]

TargetsB-lymphocyte antigen CD19Transforming growth factor beta

Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Yongtai Rec Biotechnology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Yongtai Rec Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, Diffuse

Inactive IndicationsN/A

Other Information

ATC CodeN/A